HR Execs on the Move

Otsuka America

www.otsuka-us.com

 
There are three Otsuka pharmaceutical industry companies in the U.S.: Otsuka America Pharmaceutical, Inc. (OAPI) successfully commercializes Otsuka-discovered and in-licensed products in North America. Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) clinically develops and registers innovative healthcare products on a global basis. Otsuka Maryland Medicinal Laboratories, Inc. (OMML) is a basic research center investigating pharmacological compounds.
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
Jim Forker
Associate Director, Nephrology Operations Profile
Dan Monahan
VP, CNS Marketing and Portfolio Strategy Profile
Cara Klose
Associate Director, HR Business Partner Profile
Rich Dunn
Associate Director, Talent Acquisition Profile
Anuradha Rana
Executive Director People Enablement and Business Services Profile

Jobs

Similar Companies

Maag Prescription

Maag Prescription is a Pocatello, ID-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Intuitive

Intuitive Surgical, Inc. is an American corporation that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System.

Patton's Pharmacy

Patton's Pharmacy is a Santa Monica, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Paratek Pharmaceuticals

Paratek Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of antibacterial therapeutics based upon tetracycline chemistry in the United States. Its lead product candidate, omadacycline, is a tetracycline-derived and broad-spectrum antibiotic developed in oral tablet and intravenous formulations for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections. The company has special protocol assessment agreements with Food and Drug Administration for the Phase III trials planned in ABSSSI and CABP. It is also developing sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for use in the treatment of acne and rosacea. The company has collaborative research and license agreement with Actavis to research, develop, and commercialize tetracycline products; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and collaboration agreement with Purdue Pharmaceuticals L.P. to commercialize Intermezzo. Paratek Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.